Watchtower Advisors’s Royalty Pharma RPRX Stock Holding History

Watchtower Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-100,000	Closed	-$3.6M	–	20
2025 Q2	$3.6M	Buy	+100,000	New	+$3.31M	2.13%	16

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Watchtower Advisors's RPRX Position: Q3 2025 in Review

Watchtower Advisors sold out of Royalty Pharma (RPRX) in Q3 2025, closing a stake of 100,000 shares — an estimated $3.6M sold.

Watchtower Advisors first reported a position in RPRX in Q2 2025 and held it in 1 quarter. The position peaked at $3.6M in Q2 2025. 487 funds tracked by Wall St. Rank hold RPRX as of Q3 2025.

Watchtower Advisors reported no remaining Royalty Pharma position as of Q3 2025 after selling out during the quarter.
Watchtower Advisors sold 100,000 Royalty Pharma shares in Q3 2025, an estimated $3.6M.
Watchtower Advisors first reported a position in Royalty Pharma in Q2 2025 and held it in 1 quarter.
Watchtower Advisors's Royalty Pharma position peaked at $3.6M in Q2 2025.
487 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2025.

Based on Watchtower Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.